NextFin News - EQT AB has engaged Goldman Sachs Group Inc. and Morgan Stanley to explore strategic options for WS Audiology A/S, including a potential initial public offering or a private sale that could value the hearing-aid manufacturer at approximately €7 billion ($7.5 billion). The Swedish private equity firm, which formed the company through the 2019 merger of Sivantos and Widex, is testing the appetite for healthcare assets as the European IPO market shows signs of a tentative recovery. According to Bloomberg, the deliberations are in the early stages, and the final valuation will depend on market conditions and the company’s ability to sustain its recent margin improvements.
The move comes as WS Audiology navigates a complex financial landscape characterized by high leverage and a recent return to profitability. Fitch Ratings, which affirmed the company’s 'B' rating with a stable outlook in March 2026, noted that while the business profile remains solid, its credit profile is constrained by weaker free cash flow and high debt levels. Fitch analysts project that the company’s EBITDA leverage will only gradually fall toward 6x by 2028, a trajectory that hinges on the successful rollout of new product lines and a sustained return to organic growth. This cautious credit perspective serves as a necessary counterweight to the more optimistic valuation targets circulating in the M&A market.
For the 2025/26 fiscal year, WS Audiology has guided for organic revenue growth of 0% to 4%, reflecting what management describes as an "uncertain macroeconomic environment." Despite these headwinds, the company expects its EBITDA margin to expand by approximately one percentage point, supported by cost-cutting measures implemented in 2024 and 2025. S&P Global Ratings has echoed this sentiment, forecasting an adjusted EBITDA margin of 17.5% to 18.0% for 2025. These internal efficiencies are critical for EQT as it seeks to justify a €7 billion price tag to potential public investors or private equity peers who are increasingly disciplined about cash flow generation.
The hearing-aid industry remains a highly consolidated "pure play" sector, where WS Audiology competes against giants like Sonova Holding AG and Demant A/S. While the long-term demographics of an aging global population provide a structural tailwind, the sector has faced pressure from the rise of over-the-counter (OTC) hearing aids and shifting retail dynamics. EQT’s decision to hire banks now suggests a desire to capitalize on the company’s status as a leading online retailer through its audibene platform, which has helped it redefine the competitive landscape across more than 125 countries.
A successful exit would mark a significant milestone for EQT’s healthcare portfolio, yet the path to a €7 billion valuation is not without obstacles. Market participants remain wary of the "valuation gap" that has plagued recent European listings, where private equity expectations have frequently clashed with public market skepticism regarding high-leverage structures. If a public listing fails to materialize, EQT may pivot toward a minority stake sale or a secondary buyout, though the pool of buyers capable of absorbing a multi-billion-euro healthcare asset remains limited in the current interest rate environment.
Explore more exclusive insights at nextfin.ai.
